ALZFORUM4d
Lecanemab Tops Other Antibodies at Binding Soluble Aβ Aggregates
Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...
The Financial Express1d
Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection: GlobalData
There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...
The American Journal of Managed Care12d
Discarded Lecanemab Leads to Medicare Drug Waste of Up to $336 Million
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
Why thousands of dementia sufferers are being denied the new miracle drug
In late 2022, the results of a groundbreaking stage three trial for a ‘miracle’ new Alzheimer’s drug lecanemab were hailed as ...
HealthDay on MSN7d
Annual Wasteful Spending on Lecanemab Estimated at $133 to $336 Million
Annual wasteful spending on discarded lecanemab is anticipated to range between $133 and $336 million, given current vial ...
Medpage Today on MSN12d
Alzheimer's Drug in Smaller Vial Sizes Could Save Medicare Hundreds of Millions
An estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...
STAT3d
U.K.’s cost-effectiveness agency says Alzheimer’s drug donanemab does not provide good value
For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...
The Daily Telegraph4d
Why thousands of dementia sufferers are being denied the new miracle drug
In late 2022, the results of a groundbreaking stage-three trial for a ‘miracle’ new Alzheimer’s drug, lecanemab, were hailed as momentous. Finally, for the first time, a drug had slowed the ...
Eisai will request reconsideration of initial decision for lecanemab in Australia
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to ...